Evidence map›Paper›PMID 39943159›Full record

ReviewAnimals : an open access journal from MDPI2025

Advancing Veterinary Oncology: Next-Generation Diagnostics for Early Cancer Detection and Clinical Implementation.

Aya Hasan Alshammari, Takuya Oshiro, Umbhorn Ungkulpasvich, Junichi Yamaguchi, Masayo Morishita, Sura Abbas Khdair, Hideyuki Hatakeyama, Takaaki Hirotsu, Eric di Luccio

Abstract readReview
In one paragraph

Review in Animals : an open access journal from MDPI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Transcriptomic profiling of a canine malignant eyelid melanoma.Brazilian journal of veterinary medicine · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aya Hasan AlshammariHirotsu Bioscience Inc., New Otani Garden Court 22F, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, Japan.
Takuya OshiroHirotsu Bioscience Inc., New Otani Garden Court 22F, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, Japan.
Umbhorn UngkulpasvichHirotsu Bioscience Inc., New Otani Garden Court 22F, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, Japan.ORCID 0000-0002-9735-3798
Junichi YamaguchiHirotsu Bioscience Inc., New Otani Garden Court 22F, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, Japan.ORCID 0000-0002-7194-5891
Masayo MorishitaHirotsu Bioscience Inc., New Otani Garden Court 22F, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, Japan.
Sura Abbas KhdairClinical Pharmacy Department, College of Pharmacy, Al-Mustansiriya University, Baghdad 10052, Iraq.
Hideyuki HatakeyamaHirotsu Bioscience Inc., New Otani Garden Court 22F, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, Japan.
Takaaki HirotsuHirotsu Bioscience Inc., New Otani Garden Court 22F, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, Japan.ORCID 0009-0009-3276-6020
Eric di LuccioHirotsu Bioscience Inc., New Otani Garden Court 22F, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, Japan.ORCID 0000-0002-2256-2157

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a leading cause of death among companion animals, with many cases diagnosed at advanced stages when clinical signs have appeared, and prognosis is poor. Emerging diagnostic technologies, including Artificial Intelligence (AI)-enhanced imaging, liquid biopsies, molecular diagnostics, and nematode-based screening, can improve early detection capabilities in veterinary medicine. These tools offer non-invasive or minimally invasive methods to facilitate earlier detection and treatment planning, addressing the limitations of traditional diagnostics, such as radiography and tissue biopsies. Recent advancements in comparative oncology, which leverage the biological similarities between human and companion animal cancers, underscore their translational value in improving outcomes across species. Technological advances in genomics, bioinformatics, and machine learning are driving a shift toward precision medicine, enabling earlier detection, personalized treatments, and monitoring of disease progression. Liquid biopsy testing detects circulating tumor DNA and tumor cells, providing actionable insights into tumor genetics without invasive procedures. Imaging systems enhance diagnostic precision, offering consistent and accurate tumor identification across veterinary practices, while portable innovations like

Indexed as

Artificial Intelligence-enhanced imagingcompanion animal cancercomparative oncologyliquid biopsymolecular biomarkersmolecular diagnosticsOne HealthOne Medicineprecision medicine

Identifiers

PMID39943159
PMCPMC11816279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.